dc.contributor.author |
Weisel, Katja |
|
dc.date.accessioned |
2020-11-10T06:26:11Z |
|
dc.date.available |
2020-11-10T06:26:11Z |
|
dc.date.issued |
2020 |
|
dc.identifier.issn |
1029-2403 |
|
dc.identifier.uri |
http://hdl.handle.net/10900/109382 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Taylor & Francis Ltd |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.1080/10428194.2019.1648806 |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials |
de_DE |
dc.type |
Article |
de_DE |
utue.kommentar.intern |
"Published online: 22 Oct 2019" |
de_DE |
utue.quellen.id |
20200715072417_02450 |
|
utue.publikation.seiten |
37-46 |
de_DE |
utue.personen.roh |
Weisel, Katja |
|
utue.personen.roh |
Majer, Istvan |
|
utue.personen.roh |
DeCosta, Lucy |
|
utue.personen.roh |
Oriol, Albert |
|
utue.personen.roh |
Goldschmidt, Hartmut |
|
utue.personen.roh |
Ludwig, Heinz |
|
utue.personen.roh |
Campioni, Marco |
|
utue.personen.roh |
Szabo, Zsolt |
|
utue.personen.roh |
Dimopoulos, Meletios |
|
dcterms.isPartOf.ZSTitelID |
Leukemia & Lymphoma |
de_DE |
dcterms.isPartOf.ZS-Issue |
1 |
de_DE |
dcterms.isPartOf.ZS-Volume |
61 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |